VIVUS Shares Dip and 4 Healthcare Movers to Notice Now
Vivus (NASDAQ:VVUS) shares are down more than 7 percent Wednesday.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
Abbott Laboratories (NYSE:ABT) has detailed its plans for the late-stage development of the regimen for phase II data on its hepatitis C virus (HCV) as the firm also is investigating a regimen consisting of three direct acting antivirals (DAA) for the treatment of HCV in genotype 1 (GT1) non-cirrhotic treatment-naïve as well as treatment-experienced patients. The DAAs which will be studied are ABT-450/r (protease inhibitor and ritonavir), ABT-267 (NS5A inhibitor) and ABT-333 (non-nucleoside polymerase inhibitor).
Pfizer (NYSE:PFE) is among the Dow components of the United States bond market and has a yield on a 30-year bond at 3.7 percent, although the market as a whole has a yield on the 10-year note currently around 1.62 percent and the yield on the 30-year bond around 2.76 percent. Other Dow components with more than adequate yields include Johnson & Johnson (NYSE:JNJ) at 3.5 percent, Merck (NYSE:MRK) at 3.8 percent, and Verizon (NYSE:VZ) at 4.8 percent.
Don’t Miss: Is a Sale in AMD’s Future?